Ipamorelin 10 mg

• Ipamorelin 10 mg — Sterling Knight Pharmaceuticals
• Category: Peptide / Growth Hormone Secretagogue (GHSR Agonist)
• Brand: Sterling Knight Pharmaceuticals
• Strength: 10 mg (lyophilised peptide)
• Form: Sterile vial for laboratory reconstitution
• Packing: 1 vial
• Origin: United Kingdom
• Research Use: For qualified laboratory and analytical work only. Not for human or veterinary use.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide and highly selective agonist of the ghrelin receptor (GHSR1a), designed to stimulate growth hormone (GH) release with minimal effect on ACTH or cortisol. It represents a newer generation of GH secretagogues with improved selectivity compared with classical GHRP peptides.

• Sequence: Aib–His–D-2-Nal–D-Phe–Lys-NH
• Class: Growth Hormone Secretagogue (GHSR agonist)
• Molecular Weight: ~711.8 g/mol
• CAS Number: 170851-70-4

Its clean endocrine profile makes it useful for modelling GH pulses and IGF-1 axis behavior without significant adrenal-axis activation.

Key Research Highlights

1. Selective GHSR Agonism

Ipamorelin activates GHSR1a, inducing pulsatile GH secretion similar to endogenous ghrelin signalling. Importantly, studies show:

• No significant rise in ACTH or cortisol
• Minimal prolactin elevation
• Highly GH-focused endocrine response

2. Human PK/PD Characteristics

• Terminal half-life: ~2 hours
• GH peak occurs at ~0.67 hours post-administration
• Rapid return to baseline, ideal for pulse modelling

3. Anti-Doping Relevance

GHSR agonists and GH-releasing factors, including ipamorelin, are banned by WADA under class S2.

Research Applications

• Modelling GH pulsatility and IGF-1 axis signalling
• Short half-life GH secretagogue for PK/PD experiments
• Reference standard for LC-MS/MS anti-doping method development
• Endocrine pathway studies involving GHSR activation

Potential Side Effects & Class-Based Risks

While ipamorelin shows improved selectivity, GH-axis stimulation may cause:

• Headache
• Transient flushing
• Fluid retention / edema
• Alterations in glucose handling (context-dependent)

All GH secretagogues fall under WADA S2, posing doping-test consequences in applicable settings.

Handle strictly as a bioactive peptide with appropriate PPE and biosafety protocols.

Compliance & Legal Notice

• FOR RESEARCH USE ONLY – Not for human consumption
• Not a medicine, supplement, or veterinary preparation
• Not intended for body enhancement or performance use
• Must be used only by qualified personnel under laboratory SOPs
• WADA Category: S2 — Peptide hormones & releasing factors

Technical Data Table

Intended Use

Laboratory / analytical / in-vitro research only

Research chemical — not for human or veterinary use.